ClinicalTrials.gg
CompletedNCT03660241Updated Mar 22, 2022Results posted

A Renal Impairment Study for PF-04965842

A Phase 1 interventional study of PF-04965842 in Renal Impairment, sponsored by Pfizer. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-22.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Enrollment
23rd of 36
23 · median 30
Started
2018
with 2 others
Phase 1
23 of 37
2 open now
Registered
24th of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 23rd largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2018, is one of 23 in phase 1, and was the 24th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

This study is a phase 1 non-randomized, open-label, single-dose, parallel-group study of PF 04965842 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with moderate renal impairment (Part 2).

Read the detailed description

This is a Phase 1 non randomized, open label, single dose, parallel cohort, multisite study to investigate the effect of renal impairment on the pharmacokinetics, safety and tolerability of PF-04965842 after a single 200 mg oral dose. Subjects will be selected and categorized into normal renal function or renal impairment groups based on their estimated glomerular filtration rate. Part 1: A total of approximately16 subjects will be enrolled; approximately 8 subjects with severe renal impairment and approximately 8 with normal renal function. After statistical evaluation of results from Part 1, Part 2 may be conducted and approximately 8 subjects with moderate renal impairment will be enrolled. The total duration of participation from the Screening Visit to Day 4 will be a maximum of 31 days and from the Screening Visit to Follow-up Contact/Visit will be a maximum of 67 days.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Breath alcohol test at Screening and Day -1 must be negative.
  • (BMI) of ≥ 17.5 to ≤ 40.0 kg/m2; and a total body weight >50 kg (110 lb).

Additional inclusion criteria for subjects with renal impairment:

  • Meet the following criteria during the screening period based on the MDRD equation:

    • Severe renal impairment: eGFR \<30 mL/min, but not requiring hemodialysis.
    • Moderate renal impairment (Part 2 only): eGFR ≥30 mL/min and \<60 mL/min.
  • Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).
  • Stable concomitant drug regimen.

Exclusion criteria

Exclusion Criteria:

  • Renal transplant recipients.
  • Urinary incontinence without catheterization.
  • Subjects with infections within the past 3 months (for example, those requiring hospitalization, or as judged by the Investigator), evidence of any infection (including influenza) within the past 7 days prior to baseline, history of disseminated herpes simplex infection or recurrent or disseminated herpes zoster.
  • Subjects with a or with a history of malignancy, with the exception of adequately treated or excised non- basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
  • History of or current positive results for , , .

Additional exclusion criteria for subjects with renal impairment:

  • Subjects requiring hemodialysis and peritoneal dialysis.
  • Screening BP ≥ 180 mm Hg (systolic) or ≥ 110 mm Hg (diastolic).
  • Screening supine 12-lead demonstrating >470 msec or a QRS interval >120 msec.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    PF-04965842

    PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor

    Drug: PF-04965842

Interventions

  • PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) for PF-04965842

    Maximum observed plasma PF-04965842 concentration.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

  2. Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-04965842

    Area under the plasma PF-04965842 concentration-time profile from time 0 extrapolated to infinite time.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

  3. Maximum Observed Plasma Concentration (Cmax) for PF-06471658 (M1)

    Maximum observed plasma concentration for active metabolite, PF-06471658 (M1).

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

  4. Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06471658 (M1)

    Area under the plasma concentration-time profile from time 0 extrapolated to infinite time for active metabolite, PF-06471658 (M1).

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

  5. Maximum Observed Plasma Concentration (Cmax) for PF-07055087 (M2)

    Maximum observed plasma concentration for active metabolite, PF-07055087 (M2).

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

  6. Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-07055087 (M2)

    Area under the plasma concentration-time profile from time 0 extrapolated to infinite time for active metabolite, PF-07055087 (M2).

    Time frame: 0 (pre-dose), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Adverse events (AEs): any untoward medical occurrence in a clinical investigation subject administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Treatment-related TEAEs were any untoward medical occurrence attributed to study treatment. Causality to study treatment was determined by the investigator.

    Time frame: Baseline up to Follow-Up (Day 36)

  2. Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

    Protocol-required safety laboratory assessments included chemistry, hematology, and urinalysis (and microscopy, if needed). Each parameter was evaluated against commonly used and widely accepted criteria.

    Time frame: Baseline, post-dose on Day 1, Day 2 and Day 4.

  3. Number of Participants With Clinically Significant Vital Sign Values

    Vital sign data included blood pressure and pulse rate. Clinical significance was assessed by the investigator.

    Time frame: Day 1 (pre-dose) and Day 4

  4. Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values

    Clinical significance of ECG data was assessed by the investigator.

    Time frame: Baseline, post-dose on Day 1 and on Day 4

07

Results

Posted Dec 17, 2020

Participant flow

Participant flow — Overall Study
MilestoneNormal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Started878
Completed878
Not completed000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) for PF-04965842

Maximum observed plasma PF-04965842 concentration.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for PF-04965842
nanogram per milliliter (ng/mL)Normal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Maximum Observed Plasma Concentration (Cmax) for PF-049658421174 ± 561626 ± 311164 ± 80
Statistical analysis
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Ratio of adjusted geometric means: 138.49 · 90% CI 93.74 to 204.61
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Ratio of adjusted geometric means: 99.11 · 90% CI 57.30 to 171.43
PrimaryArea Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-04965842

Area under the plasma PF-04965842 concentration-time profile from time 0 extrapolated to infinite time.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-04965842
nanogram*hour per milliliter (ng*hr/mL)Normal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-049658424827 ± 658828 ± 375855 ± 73
Statistical analysis
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Ratio of adjusted geometric means: 182.91 · 90% CI 117.09 to 285.71
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Ratio of adjusted geometric means: 121.32 · 90% CI 68.32 to 215.41
PrimaryMaximum Observed Plasma Concentration (Cmax) for PF-06471658 (M1)

Maximum observed plasma concentration for active metabolite, PF-06471658 (M1).

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for PF-06471658 (M1)
nanogram per milliliter (ng/mL)Normal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Maximum Observed Plasma Concentration (Cmax) for PF-06471658 (M1)193.7 ± 54192.8 ± 65325.0 ± 81
Statistical analysis
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Ratio of adjusted geometric means: 99.51 · 90% CI 59.80 to 165.57
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Ratio of adjusted geometric means: 167.79 · 90% CI 97.20 to 289.64
PrimaryArea Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06471658 (M1)

Area under the plasma concentration-time profile from time 0 extrapolated to infinite time for active metabolite, PF-06471658 (M1).

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06471658 (M1)
nanogram*hour/milliliter (ng*hr/mL)Normal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06471658 (M1)872.6 ± 441346 ± 432505 ± 45
Statistical analysis
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Ratio of adjusted geometric means: 154.22 · 90% CI 105.11 to 226.26
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Ratio of adjusted geometric means: 287.06 · 90% CI 196.72 to 418.89
PrimaryMaximum Observed Plasma Concentration (Cmax) for PF-07055087 (M2)

Maximum observed plasma concentration for active metabolite, PF-07055087 (M2).

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for PF-07055087 (M2)
nanogram per milliliter (ng/mL)Normal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Maximum Observed Plasma Concentration (Cmax) for PF-07055087 (M2)241.3 ± 34331.6 ± 21429.3 ± 28
Statistical analysis
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Ratio of adjusted geometric means: 137.43 · 90% CI 106.82 to 176.81
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Ratio of adjusted geometric means: 177.92 · 90% CI 135.91 to 232.92
PrimaryArea Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-07055087 (M2)

Area under the plasma concentration-time profile from time 0 extrapolated to infinite time for active metabolite, PF-07055087 (M2).

Time frame:
0 (pre-dose), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-07055087 (M2)
nanogram*hour per milliliter (ng*hr/mL)Normal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-07055087 (M2)1476 ± 313981 ± 388433 ± 25
Statistical analysis
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Ratio of adjusted geometric means: 269.78 · 90% CI 196.61 to 370.18
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Ratio of adjusted geometric means: 571.43 · 90% CI 447.27 to 730.05
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Adverse events (AEs): any untoward medical occurrence in a clinical investigation subject administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Treatment-related TEAEs were any untoward medical occurrence attributed to study treatment. Causality to study treatment was determined by the investigator.

Time frame:
Baseline up to Follow-Up (Day 36)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsNormal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
All-causality110
Treatment-related010
SecondaryNumber of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

Protocol-required safety laboratory assessments included chemistry, hematology, and urinalysis (and microscopy, if needed). Each parameter was evaluated against commonly used and widely accepted criteria.

Time frame:
Baseline, post-dose on Day 1, Day 2 and Day 4.
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsNormal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)668
SecondaryNumber of Participants With Clinically Significant Vital Sign Values

Vital sign data included blood pressure and pulse rate. Clinical significance was assessed by the investigator.

Time frame:
Day 1 (pre-dose) and Day 4
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Values
ParticipantsNormal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Number of Participants With Clinically Significant Vital Sign Values000
SecondaryNumber of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values

Clinical significance of ECG data was assessed by the investigator.

Time frame:
Baseline, post-dose on Day 1 and on Day 4
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values
ParticipantsNormal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values000
Post-hocUnbound Maximum Observed Plasma Concentration (Cmax,u) of the Active Moiety

The unbound maximum observed plasma concentration for active moiety, calculated as the sum of unbound Cmax for PF-04965842 and active metabolites, PF-06471658 (M1) and PF-07055087 (M2), adjusted for the relative potencies of the metabolites.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.
Reported as:
Geometric mean · nanomolar (nM)
Unbound Maximum Observed Plasma Concentration (Cmax,u) of the Active Moiety
nanomolar (nM)Normal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Unbound Maximum Observed Plasma Concentration (Cmax,u) of the Active Moiety2099 ± 382810 ± 202718 ± 41
Statistical analysis
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Ratio of adjusted geometric means: 133.87 · 90% CI 102.45 to 174.92
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Ratio of adjusted geometric means: 129.49 · 90% CI 92.86 to 180.57
Post-hocUnbound Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf,u) of the Active Moiety

The unbound area under the plasma concentration-time profile from time 0 extrapolated to infinite time for active moiety, calculated as the sum of unbound AUCinf for PF-04965842 and active metabolites, PF-06471658 (M1) and PF-07055087 (M2), adjusted for the relative potencies of the metabolites.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.
Reported as:
Geometric mean · nanomolar*hour (nM*hr)
Unbound Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf,u) of the Active Moiety
nanomolar*hour (nM*hr)Normal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
Unbound Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf,u) of the Active Moiety9955 ± 4020920 ± 2828940 ± 23
Statistical analysis
  • Normal Renal Function vs Moderate Renal Impairment · ANOVA · Ratio of adjusted geometric means: 210.20 · 90% CI 154.60 to 285.80
  • Normal Renal Function vs Severe Renal Impairment · ANOVA · Ratio of adjusted geometric means: 290.68 · 90% CI 217.39 to 388.69

Adverse events

Collected over Baseline up to Follow-Up (Day 36). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Renal Function0/8 (0%)0/8 (0%)1/8 (12.5%)
Moderate Renal Impairment0/7 (0%)0/7 (0%)1/7 (14.3%)
Severe Renal Impairment0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Most frequent other events
EventNormal Renal FunctionModerate Renal ImpairmentSevere Renal Impairment
NauseaGastrointestinal disorders0/81/70/8
ToothacheGastrointestinal disorders1/81/70/8
HeadacheNervous system disorders0/81/70/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Normal Renal FunctionModerate Renal ImpairmentSevere Renal ImpairmentTotal
Mean59.8 ± 4.7165.7 ± 8.3461.0 ± 14.4662.0 ± 9.96
Sex: Female, Male
Sex: Female, Male(Participants)Normal Renal FunctionModerate Renal ImpairmentSevere Renal ImpairmentTotal
Female2417
Male63716
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Normal Renal FunctionModerate Renal ImpairmentSevere Renal ImpairmentTotal
Hispanic or Latino44412
Not Hispanic or Latino43411
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Normal Renal FunctionModerate Renal ImpairmentSevere Renal ImpairmentTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1113
White66719
More than one race1001
Unknown or Not Reported0000
08

Study locations

4 sites
  • University of Miami Division of Clinical Pharmacology
    Miami, Florida 33136, United States
  • University of Miami, Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Brussels Clinical Research Unit
    Brussels, Be-bru B-1070, Belgium
09

References and documents

Publications

  • Wang EQ, Le V, Winton JA, Tripathy S, Raje S, Wang L, Dowty ME, Malhotra BK. Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. J Clin Pharmacol. 2022 Apr;62(4):505-519. doi: 10.1002/jcph.1980. Epub 2022 Feb 15. PubMed 34637151 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Nov 2019, 13 months.

Results were first posted in Dec 2020, 1 year 1 month after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 13 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2018
First posted
Sep 6, 2018
StartActual
Oct 5, 2018
Primary completionActual
Nov 5, 2019
CompletionActual
Nov 5, 2019
Results first posted
Dec 17, 2020
Last update
Mar 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03660241
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 6, 2018
Start date
Oct 5, 2018
Primary completion
Nov 5, 2019
Completion
Nov 5, 2019
Results posted
Dec 17, 2020
Last update
Mar 22, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion